The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The adoption of automated molecular platforms for blood screening has emerged as a key strategy among leading market players, significantly accelerating market growth. Blood screening tests are specifically developed to ensure the safety of donated blood units and to identify markers of transfusion-transmissible infections (TTIs). The rising number of blood donations and an expanding donor base, coupled with growing awareness about the safety of donated blood, are driving the market forward. Additionally, the increasing prevalence of infectious diseases, along with various government initiatives aimed at improving blood safety standards, are major factors propelling the growth of the blood screening market.
Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/blood-screening-market-102552
Blood Screening Market: Market Trend
The Blood Screening Market is witnessing a strong shift towards automation and advanced molecular testing techniques. Increasing awareness about transfusion-transmitted infections (TTIs) and the need for early detection of diseases are driving innovation. Technologies like nucleic acid testing (NAT) and chemiluminescence immunoassays are increasingly adopted to enhance accuracy and speed in blood screening processes. Furthermore, strategic partnerships between diagnostic companies and healthcare institutions are fueling the development of high-throughput screening systems, enhancing the efficiency of the Blood Screening Market.
Blood Screening Market: Market Growth
The Blood Screening Market is poised for significant growth over the coming years, driven by rising demand for safe blood transfusion procedures and the increasing prevalence of infectious diseases. Government initiatives to ensure blood safety, coupled with rising healthcare expenditure, are expected to accelerate market expansion. Additionally, the growing number of blood donations globally is contributing to the demand for reliable and efficient screening methods, pushing the Blood Screening Market towards a robust growth trajectory.
List Of Key Companies Profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Other Players
Blood Screening Market: Restraining Factors
Despite its promising outlook, the Blood Screening Market faces several restraining factors. High operational costs and the substantial initial investment required for advanced screening technologies limit adoption, especially in low- and middle-income countries. Furthermore, stringent regulatory frameworks and complex approval processes for new screening devices can delay market entry for innovative solutions. The shortage of skilled laboratory professionals also poses a challenge to the widespread adoption of sophisticated blood screening systems.
Blood Screening Market: Market Segmentation
The Blood Screening Market is segmented based on technology, product & service, end-user, and region. In terms of technology, the Blood Screening Market includes nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, and western blot assay. NAT is expected to dominate the Blood Screening Market due to its high sensitivity and ability to detect infections during the window period.
When looking at product and service, the Blood Screening Market covers reagents & kits, instruments, and software & services. Reagents & kits hold a major share in the Blood Screening Market as they are essential consumables for every screening process. Additionally, increasing demand for user-friendly and rapid diagnostic kits is further supporting the growth of this segment within the Blood Screening Market.
By end-user, the Blood Screening Market is categorized into blood banks, hospitals, and clinical laboratories. Blood banks form the largest segment as they play a crucial role in maintaining blood supply safety. Hospitals are also rapidly increasing their share in the Blood Screening Market owing to rising patient inflow and the need for in-house blood testing facilities.
Geographically, the Blood Screening Market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America currently leads the Blood Screening Market due to advanced healthcare infrastructure and favorable reimbursement policies. However, the Asia-Pacific region is expected to witness the fastest growth in the Blood Screening Market, driven by increasing healthcare investments and rising awareness about blood safety.
Blood Screening Market: Regional Analysis
Regionally, North America dominates the Blood Screening Market, owing to technological advancements, government support for blood safety, and the presence of key market players. Europe follows closely, supported by strong healthcare regulations and a growing elderly population in need of blood transfusions. Meanwhile, the Asia-Pacific region presents lucrative opportunities for the Blood Screening Market, fueled by large population bases, improved healthcare facilities, and increasing incidences of infectious diseases. Emerging economies like India and China are at the forefront of this regional growth, making Asia-Pacific a focal point for future expansion of the Blood Screening Market.
Key Industry Developments:
In June 2021, Grail, a U.S.-based biotechnology and pharmaceutical company, announced the launch of its Galleri blood test — an innovative multi-cancer screening diagnostic designed to detect the presence of multiple cancer types. With this groundbreaking test, the company aims to screen approximately 50 million individuals following its launch and is targeting full FDA approval by 2023.